Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.0752W HIGH $29.23
Volume
3.69 M
Value Traded
51.16 M
Short % Float
27.03%
Days to Cover
4.8
-6.94%Week
-6.4%1 Month
+10.57%3 Month
-34.49%6 Month
+117.25%5 Year
+65.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.57 B
EPS (TTM)
-1.07
P/E Ratio
-
Ent. Value
10.95 B
Total Shares
797.75 M
Float Shares
152.24 M
Insiders
80.92%
Institutions
17.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SMMT Catalyst Timeline
Dated clinical, regulatory and corporate events for Summit Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Summit Therapeutics Inc.
805Total events
9Upcoming
175Tier-1 (high impact)
2011 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationIvonescimabApprovedPresentation
HARMONi-GI1 data featured in Presidential Symposium II at ESMO 2026 Congress, Madrid
advanced biliary tract cancersource ↗
▲Late-BreakerIvonescimabApprovedPresentation
HARMONi-GI1 ivonescimab plus chemo vs durvalumab plus chemo selected as ESMO 2026 Late-Breaking Abstract
first-line advanced biliary tract cancersource ↗
●Oral PresentationIvonescimabApprovedPresentation
Phase Ib/II AK112 first-line IMDC favorable-risk aRCC oral presentation at ESMO 2026 (Abstract #3592O)
advanced renal cell carcinomasource ↗
▲Primary Endpoint MetIvonescimabApprovedClinical Data
Ivonescimab regimen achieved statistically significant and clinically meaningful OS superiority over durvalumab regimen
advanced biliary tract cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
HARMONi-GI1 Phase III topline: ivonescimab + chemo met OS primary endpoint vs durvalumab + chemo
advanced biliary tract cancersource ↗
●Safety Data UpdateIvonescimabApprovedClinical Data
Manageable safety profile consistent with prior Phase III studies; no additional safety signals
advanced biliary tract cancersource ↗
▲Secondary Endpoint DataIvonescimabApprovedClinical Data
Key secondary endpoints met: PFS HR 0.61, ORR 53.8% vs 32.5%, DCR 91.5% vs 77.8%
advanced biliary tract cancersource ↗
●Poster PresentationIvonescimabApprovedPresentation
Phase II neoadjuvant ivonescimab plus gemcitabine/nab-paclitaxel in pancreatic cancer poster at ESMO 2026 (Abstract #3161P)
borderline resectable pancreatic cancersource ↗
●Poster PresentationIvonescimabApprovedPresentation
Phase II AK112 plus radiotherapy and nab-paclitaxel in 2L gastric/GEJ adenocarcinoma poster at ESMO 2026 (Abstract #2898P)
gastric or gastroesophageal junction adenocarcinomasource ↗
▲Partnership / LicenseIvonescimabApprovedCorporate
Summit and Lunit announce research agreement to apply Lunit SCOPE IO AI pathology platform to ivonescimab immuno-oncology development
▲Trial InitiationIvonescimabApprovedTrial
Initiation of Phase II/III EA2251 of ivonescimab plus chemotherapy in biliary tract cancer
biliary tract cancersource ↗
▲Partnership / LicenseIvonescimabApprovedCorporate
Summit announced clinical trial collaboration with ECOG-ACRIN for registration-enabling Phase II/III study EA2251 in BTC
advanced biliary tract cancersource ↗
●Trial InitiationIvonescimabApprovedTrial
Initiation and opening of clinical trial sites for Phase II SMT112-216 study of ivonescimab-based regimens in advanced ccRCC
previously untreated advanced clear cell renal cell carcinoma (ccRCC)source ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Five Phase III ivonescimab trials read out to date, all with positive data
NSCLC and biliary tract cancersource ↗
▲Equity OfferingCorporate
AstraZeneca completes $2.0 billion equity investment in Summit Therapeutics
◆Timing GuidancePresentation
Closing of AstraZeneca equity investment expected by end of this week
▲Partnership / LicenseIvonescimabApprovedCorporate
Summit enters clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab plus Datroway
multiple solid tumor settings including breast and lung cancersource ↗
▲Partnership / LicenseIvonescimabApprovedCorporate
Summit and AstraZeneca enter clinical collaboration to evaluate ivonescimab with sonesitatug vedotin in GI cancers
gastrointestinal cancerssource ↗
▲Equity OfferingCorporate
AstraZeneca to make $2.0 billion equity investment in Summit via convertible preferred shares
▲Oral PresentationIvonescimabApprovedPresentation
Updated HARMONi overall survival data presented at WCLC 2026
non-small cell lung cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Ivonescimab demonstrates statistically significant OS benefit vs pembrolizumab in HARMONi-2
locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expressionsource ↗
▲Primary Endpoint MetIvonescimabApprovedClinical Data
Ivonescimab demonstrates statistically significant overall survival benefit vs pembrolizumab in HARMONi-2
locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expressionsource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Updated HARMONi-2 data including OS presented at WCLC 2026
PD-L1-positive advanced NSCLCsource ↗
▲Partnership / LicenseIvonescimabApprovedCorporate
Collaborations announced with sonesitatug vedotin (Sone-Ve) and Datroway (datopotamab deruxtecan) for ivonescimab combinations
solid tumorssource ↗
▲Full ResultsIvonescimabApprovedClinical Data
Updated OS analysis from HARMONi published in The Lancet Oncology
EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancersource ↗
▲PublicationIvonescimabApprovedPresentation
HARMONi Phase III primary analysis results published in The Lancet Oncology
EGFR-mutated non-small cell lung cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Positive topline results from HARMONi-GI1 in first-line advanced biliary tract cancer
first-line advanced biliary tract cancersource ↗
▲NMPA NDA ApprovalIvonescimabApprovedEx-US Regulatory
NMPA approves ivonescimab plus chemotherapy for first-line advanced squamous NSCLC in China
first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC)source ↗
▲Supplemental ApprovalIvonescimabApprovedFDA Decision
NMPA approves ivonescimab plus chemotherapy for first-line sq-NSCLC
first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC)source ↗
●Trial InitiationIvonescimabApprovedTrial
Initiation of global Phase II/III HARMONi-GU1 trial of ivonescimab plus enfortumab vedotin in 1L bladder cancer
First-line locally advanced or metastatic urothelial carcinoma (bladder cancer)source ↗
▲Primary Endpoint MetIvonescimabApprovedClinical Data
HARMONi-GI1 met primary OS endpoint at pre-specified interim analysis
biliary tract cancersource ↗
●Quarterly UpdateCorporate
Summit reported Q2 and six months ended June 30, 2026 financial results
▲Full ResultsIvonescimabApprovedClinical Data
Updated OS analysis from HARMONi trial shows positive trend for ivonescimab plus chemo vs chemo alone
non-small cell lung cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Summit previously announced HARMONi results
non-small cell lung cancersource ↗
▲Partnership / LicenseRidinilazoleCorporate
Sale of ridinilazole to Biossil, Inc.
C. difficile infectionsource ↗
●Trial InitiationIvonescimabApprovedTrial
US clinical trial site activations for HARMONi-GI3 planned to begin this quarter
colorectal cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Updated OS analysis from HARMONi showed consistent OS trend in western and Asian patients
EGFR-mutated locally advanced or metastatic non-squamous NSCLC post-EGFR TKI therapysource ↗
◆Timing GuidanceIvonescimabApprovedPresentation
Initial study under GSK collaboration expected to begin dosing patients later this quarter
Multiple solid tumorssource ↗
▲Partnership / LicenseIvonescimabApprovedCorporate
Summit announced clinical collaboration with Arcus to evaluate ivonescimab plus casdatifan in RCC
Renal cell carcinomasource ↗
●Trial InitiationIvonescimabApprovedTrial
GSK Collaboration Trials with Risvutatug Rezetecan Expected to Start Mid-2026
solid tumors (B7-H3 expressing)source ↗
●Quarterly UpdateCorporate
Summit conference call to discuss ASCO data and ivonescimab updates
▲First Patient DosedIvonescimabApprovedTrial
Initial study with GSK B7-H3 ADC expected to begin dosing patients
multiple solid tumorssource ↗
◆R&D DayPresentation
Summit Therapeutics update conference call after ASCO 2026 Plenary Session
▲Topline ReadoutIvonescimabApprovedClinical Data
Updated overall survival analysis from HARMONi study with data cut-off June 2026
EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancersource ↗
▲Full ResultsIvonescimabApprovedClinical Data
Additional OS analysis with June 2026 data cut-off
EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancersource ↗
▲Topline ReadoutIvonescimabApprovedClinical Data
Ivonescimab plus chemotherapy demonstrated statistically significant OS benefit vs tislelizumab plus chemotherapy in 1L squamous NSCLC
squamous non-small cell lung cancersource ↗
●Oral PresentationIvonescimabApprovedPresentation
Plenary Session presentation at ASCO 2026 Annual Meeting
squamous non-small cell lung cancersource ↗
●PublicationIvonescimabApprovedPresentation
Simultaneous publication of HARMONi-6 results in The Lancet
squamous non-small cell lung cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How SMMT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-25 | Ivonescimab (AK112) | Phase 1b/2 data presentation | Phase 1b/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 9%
Mid Cap(rank 60 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ivonescimab Monoclonal antibodyNCT05899608 | Non Small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 2,538 | Dec 31, 2029 | ||||||
| Ivonescimab Monoclonal antibodyNCT05382442 | Metastatic Colorectal Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 984 | Aug 12, 2028 | ||||||
| Ivonescimab Monoclonal antibodyNCT07815665 | Metastatic Urothelial Carcinoma | Phase 2 | RECRUITING | 800 | Dec 31, 2030 | ||||||
| Ivonescimab combined with Cadonilimab Monoclonal antibodyNCT07877194 | Renal Cell Carcinoma, Clear Cell | Phase 2 | NOT YET_RECRUITING | 100 | Dec 12, 2029 | ||||||
| Ivonescimab Monoclonal antibodyNCT06396065 | Non-Squamous Non-small Cell Lung Cancer | NDA/BLA | ACTIVE NOT_RECRUITING | 420 | Dec 31, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every SMMT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ivonescimab | advanced biliary tract cancer | Phase 3 | 2026-10-25 | overall survival superiorityRead More | Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DUGGAN ROBERT WDirector, Officer (Co-Chief Executive Officer), 10% Owner | Buy | 3,810,000 573,883,879 held | $13.12 | 06/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SMMT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 2.4 % (-40 %) | 477.70 M | 32.79 M | -9.91% ( -3.60 M) |
SMMT Institutional Ownership Trends
SMMT Short Interest
Shares sold short, counted twice a month.
27.03%
Short % of Float
of tradable shares sold short
41.2M
Shares Sold Short
+0.2% vs prior count
4.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
8.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SMMT ranks across every disease it competes in
Competitive Position is a premium feature
See how SMMT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSMMT News
SMMT▼ -5.9%today
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
Summit Therapeutics' partner Akeso announced that ivonescimab plus chemotherapy demonstrated a statistically significant overall survival benefit compared to durvalumab plus chemotherapy in the Phase III HARMONi-GI1 study for advanced biliary tract cancer. The study showed a 25% reduction in the risk of death, with a median overall survival of 14.9 months for ivonescimab versus 12.1 months for durvalumab.
Read more →SMMT▼ -5.9%today
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Summit Therapeutics and Lunit have entered a research agreement to utilize Lunit's AI-powered SCOPE IO platform for tumor microenvironment analysis. This partnership aims to support Summit's immuno-oncology programs, particularly with the investigational drug ivonescimab. The collaboration seeks to leverage AI to enhance biomarker discovery and patient selection in cancer therapies.
Read more →SMMTIvonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Summit Therapeutics announced that ivonescimab data will be presented at ESMO 2026, showcasing findings from various tumor types. Notably, positive survival results from the Phase III HARMONi-GI1 study in advanced biliary tract cancer were highlighted. The company aims to expand ivonescimab's clinical development across multiple indications.
Read more →SMMTAkeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Akeso announced that Summit Therapeutics has partnered with ECOG-ACRIN for a Phase II/III trial evaluating ivonescimab in first-line biliary tract cancer. This study, EA2251, aims to compare ivonescimab with chemotherapy against existing immunotherapy standards. The trial follows positive results from a previous Phase III study, signaling potential advancements in treatment options.
Read more →SMMTSummit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics announced a collaboration with ECOG-ACRIN to conduct a Phase II/III trial evaluating ivonescimab in first-line biliary tract cancer. The study, EA2251, will compare ivonescimab with chemotherapy against established immunotherapy options. Clinical trial site activations are expected to begin in Q4 2026, aiming to address significant unmet needs in this aggressive cancer type.
Read more →SMMT▲ +6.4%on this newsshared move
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
Summit Therapeutics has launched a global Phase II study of ivonescimab for treating advanced clear cell renal cell carcinoma (ccRCC). This randomized, open-label study will evaluate ivonescimab alone and in combination with other therapies in previously untreated patients. Conducted in partnership with Akeso, the trial aims to enroll around 100 patients across the U.S. and China.
Read more →SMMTAstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics has successfully closed a $2 billion equity investment from AstraZeneca. This funding will aid in the development of ivonescimab, a promising investigational bispecific antibody targeting PD-1 and VEGF. The partnership is expected to bolster Summit's research capabilities and accelerate the drug's progress towards clinical use.
Read more →SMMTSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Summit Therapeutics has entered a clinical trial collaboration with Daiichi Sankyo and AstraZeneca to assess ivonescimab, a PD-1/VEGF bispecific antibody. This partnership aims to evaluate the drug in combination with Datroway, a TROP2-directed ADC, across various solid tumors, including breast and lung cancer. The collaboration signifies a strategic move to advance cancer treatment options.
Read more →SMMT▲ +5.9%on this newsshared move
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Summit Therapeutics has secured a $2 billion strategic equity investment from AstraZeneca, aimed at advancing cancer treatment initiatives. This collaboration will focus on the development of ivonescimab and sonesitatug vedotin. The partnership is expected to significantly enhance Summit's research capabilities and market presence in oncology.
Read more →SMMTHARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
The Phase III HARMONi-GI1 trial, conducted in China, has shown that ivonescimab combined with chemotherapy significantly improves overall survival compared to durvalumab plus chemotherapy in patients with advanced biliary tract cancer. The results will be presented at the ESMO 2026 Congress, showcasing the potential of ivonescimab as a first-in-class treatment. This study marks a significant advancement in the treatment landscape for this patient population.
Read more →SMMT▼ -5.5%on this news
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Summit Therapeutics presented updated overall survival results from the Phase III HARMONi trial at WCLC 2026. The trial showed that ivonescimab combined with chemotherapy significantly improved overall survival in both Western and Asian patients with EGFR-mutated non-small cell lung cancer. The results demonstrated consistency across geographic regions, with no new safety concerns noted.
Read more →SMMTIvonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
The HARMONi-2 study revealed that ivonescimab monotherapy significantly improves overall survival in patients with PD-L1-positive advanced NSCLC compared to pembrolizumab. The trial showed a median overall survival increase of 8.2 months, with a hazard ratio of 0.73. The results were presented at the IASLC 2026 World Conference, highlighting ivonescimab's potential as a next-generation immuno-oncology therapy.
Read more →SMMT▲ +17.3%on this news
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
Summit Therapeutics' partner Akeso announced that ivonescimab monotherapy significantly improved overall survival compared to pembrolizumab in the Phase III HARMONi-2 study for PD-L1-positive advanced NSCLC. The study, conducted in China, demonstrated positive results that will be presented at a medical conference. Ivonescimab is currently approved in China but remains investigational in other regions.
Read more →SMMT▲ +6.5%on this news
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
Summit Therapeutics' partner Akeso announced positive results from the Phase III HARMONi-GI1 study, showing that ivonescimab plus chemotherapy significantly improves overall survival compared to durvalumab plus chemotherapy in advanced biliary tract cancer. This trial is notable for being the first to demonstrate such superiority in this indication. Detailed results will be shared at an upcoming medical congress.
Read more →SMMTIvonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Summit Therapeutics has published primary analysis results from the Phase III HARMONi trial in The Lancet Oncology, showing that ivonescimab combined with chemotherapy significantly improves progression-free survival in patients with EGFR-mutated non-small cell lung cancer after third-generation EGFR TKI progression. The study involved 114 cancer centers globally and demonstrated a median PFS of 6.8 months compared to 4.4 months for the placebo group. Although the overall survival trend was positive, it did not reach statistical significance at this stage.
Read more →SMMTIvonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Summit Therapeutics announced that the National Medical Products Administration (NMPA) in China has approved ivonescimab in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC). This approval is based on the successful HARMONi-6 clinical trial, which demonstrated significant improvements in overall and progression-free survival compared to existing treatments. This marks the third approval for ivonescimab in China, highlighting its potential as a leading therapy in oncology.
Read more →SMMTSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Summit Therapeutics has announced the launch of the Phase II/III HARMONi-GU1 trial, expanding its clinical development program for ivonescimab in bladder cancer. This global study aims to evaluate the efficacy of ivonescimab in combination with an antibody-drug conjugate. The trial represents a significant step in the treatment of urothelial carcinoma.
Read more →SMMT▼ -8.8%on this news
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
Summit Therapeutics Inc. reported its financial results for Q2 and the first half of 2026, highlighting significant operational advancements. The company emphasized the clinical progress of ivonescimab, particularly following promising results from the HARMONi-6 Phase III study. These developments are expected to strengthen their position in the market.
Read more →SMMTIvonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Summit Therapeutics Inc. has reported updated overall survival results from the Phase III HARMONi trial, demonstrating that ivonescimab combined with platinum-doublet chemotherapy continues to show a favorable trend. The results indicate consistent efficacy and safety across both Asian and western patient populations compared to chemotherapy alone.
Read more →SMMT▼ -8.7%on this news
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
Summit Therapeutics Inc. will host a conference call on July 23, 2026, to discuss its second quarter financial results and operational updates. The call is set for 4:30 p.m. EDT and will be accessible via the company's website. This event highlights the company's commitment to investor relations and transparency.
Read more →About Summit Therapeutics Inc.
Headquarters601 BRICKELL KEY DRIVE, MIAMI, FL, 33131
BIOPHARMAWATCH ELITE PLUS
Trade the next SMMT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime